This medical study is exploring how long patients with HER2-positive breast cancer should receive HER2-targeted therapy. HER2-positive means the cancer cells have more HER2 proteins, which help the cancer grow. The study will compare two groups: one receiving 6 months of therapy and another receiving 12 months. The therapy involves medications like trastuzumab and pertuzumab, which are designed to block HER2 proteins and help the body destroy cancer cells.
Patients will be randomly assigned to one of the two groups. Both groups will receive similar treatments, but for different lengths of time. The study will check if 6 months of therapy is as effective as 12 months in preventing cancer from coming back. Participants will have regular check-ups and imaging tests like mammograms or MRIs.
- Study duration: Up to 10 years for follow-up after treatment.
- Potential side effects: Include fatigue, diarrhea, and rash.
- Eligibility: Must have completed certain prior treatments and meet health criteria.
Considering these points can help you decide if participating in this study is right for you.